Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa dose-escalation study of BN82451B in Huntington's disease
2013-002899-41Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Huntington disease (HD) comparing BN82451B arm with Placebo arm (2 arms). Primary endpoint: Treatment-emergent adverse events. Started Jan 2014; status: terminated.
02
Drugs
BN-82451
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2013-002899-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002899-41.